Methods for treating neurological disorders with α1A-AR partial agonists
AssigneeCuraSen Therapeutics, Inc.
InventorAnthony P. Ford
Life of this patent
Estimating the term…
Abstract
In various aspects and embodiments provided are compositions and methods for a disease or disorder in a patient such as a disease or disorder that affects the brain in a patient and treating such patient.
Claims28
A method comprising administering to a patient diagnosed with nOH or in need of treatment for nOH, an α1A-AR partial agonist, wherein the agonist is RO1151240 (dabuzalgron) or Compound B.
A method for treating a disease or condition associated with low cerebral blood flow (CBF) and/or fluctuations in CBF, said method comprising identifying a patient diagnosed with, or in need of treatment for, a disease or condition associated with low cerebral blood flow (CBF) and/or fluctuations in CBF;
- and administering to said patient an α1-AR partial agonist, wherein the agonist is RO1151240 (dabuzalgron) or Compound B.
A method of treating a patient, said method comprising identifying a patient in need of a treatment to increase cardiac output and/or to increase venous return and administering to said patient an α1A-AR partial agonist, wherein the agonist is RO1151240 (dabuzalgron) or Compound B.
Dependencies are inferred from the claim text.